HEALTH OF WOMAN.2015.5(101):28–32
 

Монотерапия бактериального вагиноза: оптимальный подход
 

Давыдова Ю. В., Шевчук Е. В., Лиманская А. Ю., Огородник А. А., Тудай В. Н., Волошина Т. В., Мокрик А. Н.

ГУ «Институт педиатрии, акушерства и гинекологии НАМН Украины»

Военно-медицинского управления службы безопасности Украины
 

В статье освещены вопросы «лучших практик» в лечении бактериального вагиноза у женщин репродуктивного возраста, планирующих беременность. Представлены вопросы предотвращения устойчивости к антибиотикам, так же, как и оценка оптимального подхода к лечению первого эпизода бактериального вагиноза. Оценен опыт применения лечения бактериального вагиноза бетадином и его эффективность.
 

Ключевые слова: бактериальный вагиноз, бетадин, лечение, устойчивость к антибиотикам.
 

Литература:

1. Allerberger F, Gareis R, Jindrak V, Struelens MJ. 2009. Antibiotic stewardship implementation in the EU: the way forward. Expert Review of Anti-Infective Therapy 7 (10):1175–83. http://dx.doi.org/10.1586/eri.09.96; PMid:19968511

2. Amadeo B, Zarb P, Muller A, Drapier N, Vankerckhoven V, Rogues AM et al. 2010. European Surveillance of Antibiotic Consumption (ESAC) point prevalence survey 2008: paediatric antimicrobial prescribing in 32 hospitals of 21 European countries. The Journal of Antimicrobial Chemotherapy 65(10):2247–52. http://dx.doi.org/10.1093/jac/dkq309; PMid:20713405

3. Brocklehurst P, Gordon A, Heatley E, Milan SJ. 2013, Jan. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 31;1.

4. Campbell NC, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F et al. 2007. Designing and evaluating complex interventions to improve health care. BMJ 334(7591):455–9. http://dx.doi.org/10.1136/bmj.39108.379965.BE; PMid:17332585 PMCid:PMC1808182

5. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, Ramsay CR, Wiffen PJ, Wilcox M. 2013. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews 4.

6. Davey P, Sneddon J, Nathwani D. 2010. Overview of strategies for overcoming the challenge of antimicrobial resistance. Expert Reviews in Clinical Pharmacology 3(5):667–86. http://dx.doi.org/10.1586/ecp.10.46; PMid:22111749

7. de Kraker ME, Wolkewitz M, Davey PG, Grundmann H. 2011. The clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin resistant Staphylococcus aureus bloodstream infections. Antimicrobial Agents and Chemotherapy 55(4):1598–605. http://dx.doi.org/10.1128/AAC.01157-10; PMid:21220533 PMCid:PMC3067153

8. Gerli S, Rossetti D, Di Renzo GC. 2003. A new approach for the treatment of bacterial vaginosis: use of polyhexamethylene biguanide. A prospective, randomized study.European Review for Medical and Pharmacological Sciences. 7:127–130.

9. House of Lords Select Committee on Science and Technology. Resistance to antibiotics. Session 2000-01. 3rd Report. London: The Stationery Office Ltd. 2001.

10. Kofoed K, Zalounina A, Andersen O, Lisby G, Paul M, Leibovici L et al. 2009. Performance of the TREAT decision support system in an environment with a low prevalence of resistant pathogens. Journal of Antimicrobial Chemotherapy 63(2):400–4. http://dx.doi.org/10.1093/jac/dkn504; PMid:19091808

11. Mc Gowan JE. 2012. Antimicrobial stewardship—the state of the art in 2011: focus on outcome and methods. Infection Control and Hospital Epidemiology 33(4):331–7. http://dx.doi.org/10.1086/664755; PMid:22418627

12. Verstraelen H, Verhelst R, Roelens K, Temmerman M. 2012, Jun. Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC Infect Dis. 28;12:148.

13. Wewalka G1, Stary A, Bosse B, Duerr HE, Reimer K. 2002. Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology 204;1:79–85.